CT News and Research

RSS

MESA, Curagita join forces to bring Diagnostic Imaging services to Germany

Medical Equipment Solutions and Applications, Europe's leader in multi-vendor service for Diagnostic Imaging systems, equipment and parts, and Heidelberg-based radiology management company Curagita are joining forces to bring new and broader solutions for a full range of Diagnostic Imaging services to the German healthcare market.

2 Jun 2014

ARIAD reports data from Iclusig Phase 2 trial in adult patients with gastrointestinal stromal tumors

ARIAD Pharmaceuticals, Inc. today announced, for the first time, data from its Phase 2 trial of Iclusig (ponatinib) in adult patients with refractory metastatic and/or unresectable gastrointestinal stromal tumors (GIST).

2 Jun 2014

Investigational drug for advanced bladder cancer shows promise for treatment of certain tumor types

A multi-center phase I study using an investigational drug for advanced bladder cancer patients who did not respond to other treatments has shown promising results in patients with certain tumor types, researchers report.

31 May 2014

Fibrogen reports FG-3019 Phase 2 study results for treatment of pancreatic cancer

FibroGen, Inc. today announced results from a Phase 2 open-label study of FG-3019, an investigational anti-fibrotic antibody, in combination with gemcitabine and erlotinib for the treatment of patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).

31 May 2014

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

Boehringer Ingelheim today announced that new data will be presented from 7 abstracts for Gilotrif (afatinib) and investigational compounds, including nintedanib and BI 836845, from its oncology pipeline at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, on May 30 – June 3, 2014.

31 May 2014

State highlights: Mo.'s declining Medicaid caseload; N.C. budget would cut Medicaid rolls; Calif. paid sick leave

Missouri is seeing a bigger decline in its Medicaid rolls than nearly any other state, a ranking that the Nixon administration attributes to an improving economy and critics blame on application snafus.

31 May 2014

Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

Promedior, Inc., today announced positive preliminary data from its Phase 2 trial of PRM-151, an anti-fibrotic immunotherapy, in patients with myelofibrosis which demonstrated biologic activity with improvements across clinically relevant measures, including bone marrow fibrosis, hemoglobin, platelets, spleen, and symptoms.

31 May 2014

3D scans uncover the truth about Richard III’s spinal condition

Researchers, led by Professor Bruno Morgan at the University of Leicester, have finally been able to describe the precise nature of King Richard III’s spinal condition. He had scoliosis, causing his spine to curve to one side. He would have had a small but noticeable defect, which is unlikely to have interfered with his ability to exercise.

30 May 2014

Tai Chi intervention offers anti-aging benefits, says study

Tai Chi, a traditional Chinese martial art and sport, has been found to be beneficial in raising the numbers of an important type of cell when three groups of young people were tested to discover the benefits of Tai Chi, brisk walking or no exercise.

29 May 2014

Georgia disputes reports of big Medicaid enrollment jump

According to the state's Department of Community Health, the increase in enrollment was about 37,000, significantly lower than the nearly 99,000 estimated by a consulting group earlier this year.

29 May 2014

Patrys reports positive results from PAT-SM6 clinical trial in patients with multiple myeloma

Patrys Limited, a clinical stage biotechnology company, is pleased to announce the clinical results from a patient treated with PAT-SM6 in combination with other marketed multiple myeloma drugs.

28 May 2014

CytRx announces Phase 2b clinical trial results of aldoxorubicin in subjects with metastatic STS

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced updated results from its ongoing multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas.

28 May 2014

Findings explain why women with bladder cancer are often diagnosed at later stage than men

Women with blood in their urine (hematuria) were less than half as likely as men with the same issue to be referred to a urologist for further tests, according to a new Vanderbilt University study.

28 May 2014

Chest CT helps identify individuals at risk for future heart attacks

Incidental chest computed tomography (CT) findings can help identify individuals at risk for future heart attacks and other cardiovascular events, according to a new study published online in the journal Radiology.

27 May 2014

BIOTRONIK ProMRI ICD trial expansion achieves FDA approval

BIOTRONIK, a leading manufacturer of cardiovascular medical devices, announced today that the Food and Drug Administration (FDA) has approved a significant expansion of its ongoing ProMRI® trial.

23 May 2014

NCCN receives $2M grant to evaluate effectiveness of volasertib in treatment of hematologic malignancies

The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has been awarded a $2-million grant from Boehringer Ingelheim Pharmaceuticals, Inc.

23 May 2014

Phase 3 data of VIVACITO study evaluating effect of T+O FDC in COPD presented at ATS conference

Boehringer Ingelheim today presented results of the VIVACITO® (NCT01559116) study, the first Phase 3 data to be reported from the TOviTO® clinical trial program, evaluating the effect of the fixed-dose combination of tiotropium and olodaterol (T+O FDC) delivered via the Respimat® inhaler on lung function in people with chronic obstructive pulmonary disease (COPD).

22 May 2014

CT News and Research

MESA, Curagita join forces to bring Diagnostic Imaging services to Germany

ARIAD reports data from Iclusig Phase 2 trial in adult patients with gastrointestinal stromal tumors

Investigational drug for advanced bladder cancer shows promise for treatment of certain tumor types

Fibrogen reports FG-3019 Phase 2 study results for treatment of pancreatic cancer

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

State highlights: Mo.'s declining Medicaid caseload; N.C. budget would cut Medicaid rolls; Calif. paid sick leave

Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

3D scans uncover the truth about Richard III’s spinal condition

Tai Chi intervention offers anti-aging benefits, says study

Georgia disputes reports of big Medicaid enrollment jump

Patrys reports positive results from PAT-SM6 clinical trial in patients with multiple myeloma

CytRx announces Phase 2b clinical trial results of aldoxorubicin in subjects with metastatic STS

Findings explain why women with bladder cancer are often diagnosed at later stage than men

Chest CT helps identify individuals at risk for future heart attacks

BIOTRONIK ProMRI ICD trial expansion achieves FDA approval

NCCN receives $2M grant to evaluate effectiveness of volasertib in treatment of hematologic malignancies

Phase 3 data of VIVACITO study evaluating effect of T+O FDC in COPD presented at ATS conference

Nevada to use federal exchange for next open enrollment

State highlights: Calif. bill on keeping small biz health plans; Colo. rating area plan approved

First Edition: May 20, 2014

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News